NewLink Genetics Corporation News Releases http://investors.linkp.com/ NewLink Genetics Corporation News Releases en NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-presents-updated-nlg802-results-immuno-oncology NLG802 , a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging safety profile Notable response in 5 th line pancreatic cancer patient re-challenged with chemotherapy after NLG802 Thu, 23 May 2019 08:30:00 -0400 NewLink Genetics Corporation News Releases 12451 NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-reports-first-quarter-2019-financial-results - Management to host conference call today at 4:30 p.m. ET AMES, Iowa , May 08, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical activities. Wed, 08 May 2019 16:01:00 -0400 NewLink Genetics Corporation News Releases 12391 NewLink Genetics to Participate in Upcoming Investor and Medical Conferences http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-participate-upcoming-investor-and-medical AMES, Iowa , May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences: Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas Management will Mon, 06 May 2019 09:00:00 -0400 NewLink Genetics Corporation News Releases 12386 NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019 http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-host-its-first-quarter-2019-conference-call-may AMES, Iowa , April 24, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical Wed, 24 Apr 2019 09:00:00 -0400 NewLink Genetics Corporation News Releases 12381 NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019 http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-presents-encouraging-phase-2-results-nlg207 AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with The GOG Foundation, Inc. Tue, 02 Apr 2019 08:00:00 -0400 NewLink Genetics Corporation News Releases 12356 NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-announces-clinical-trial-abstract-presentation AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poster Wed, 27 Feb 2019 16:30:00 -0500 NewLink Genetics Corporation News Releases 12276 NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-reports-fourth-quarter-year-end-2018-financial Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as progress in its clinical development programs. The Wed, 27 Feb 2019 16:01:00 -0500 NewLink Genetics Corporation News Releases 12271 NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-host-its-fourth-quarter-and-full-year-2018 AMES, Iowa , Feb. 07, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. The company has scheduled a conference call for 4:30 PM ET on the same day to Thu, 07 Feb 2019 09:00:00 -0500 NewLink Genetics Corporation News Releases 12221 NewLink Genetics to Participate in the Immuno-Oncology 360° Conference http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-participate-immuno-oncology-360deg-conference AMES, Iowa , Jan. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Company’s Chairman, CEO and Chief Scientific Officer, Charles J. Link, Jr , MD, will participate in the Immuno-Oncology 360 ° Conference (IO360 ° ) being held February 6 – 9, 2019 at Wed, 30 Jan 2019 09:00:00 -0500 NewLink Genetics Corporation News Releases 12196 NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting http://investors.linkp.com/news-releases/news-release-details/newlink-genetics-presents-encouraging-updated-phase-1-data Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well Sun, 02 Dec 2018 12:30:00 -0500 NewLink Genetics Corporation News Releases 12131